
MeiraGTx Holdings plc
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
MeiraGTx Holdings plc develops gene therapies for inherited retinal diseases, neurodegenerative disorders, and other serious conditions, using viral vector-based delivery and a proprietary gene regulation technology platform. It also operates manufacturing facilities to produce gene therapy products for its own pipeline and for partners.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Naylor StuartCHIEF SCI OFCR, OPHTHALMOLOGY | Sell | $294K | 27,659at $10.64 | Oct 6, 2026 |
| Forbes AlexandriaPRESIDENT & CEO | Sell | $859K | 62,000at $13.86 | Aug 18, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable MGTX activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.